Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.

[1]  S. Asgharzadeh,et al.  More than the genes, the tumor microenvironment in neuroblastoma. , 2016, Cancer letters.

[2]  J. Boudreau,et al.  KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Naranjo,et al.  A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study. , 2016 .

[4]  A. Naranjo,et al.  Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children’s Oncology Group (COG) study. , 2016 .

[5]  Sara M. Federico,et al.  Improved clinical responses with the concomitant use of an anti-GD2 monoclonal antibody and chemotherapy in newly diagnosed children with high-risk (HR) neuroblastoma (NB): Preliminary results of a phase II study. , 2016 .

[6]  A. Aguzzi,et al.  Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma , 2016, PloS one.

[7]  Gudrun Schleiermacher,et al.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Ostrovnaya,et al.  Key role for myeloid cells: Phase II results of anti‐GD2 antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblastoma , 2014, International journal of cancer.

[9]  N. Cheung,et al.  GD2-targeted immunotherapy and radioimmunotherapy. , 2014, Seminars in oncology.

[10]  S. Keir,et al.  Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program , 2014, Pediatric blood & cancer.

[11]  R. Norris,et al.  Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study , 2014, Pediatric blood & cancer.

[12]  C. Porta,et al.  Targeting PI3K/Akt/mTOR Signaling in Cancer , 2014, Front. Oncol..

[13]  Daniel J Sargent,et al.  Randomized Phase II Clinical Trials , 2014, Journal of biopharmaceutical statistics.

[14]  John M Maris,et al.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[15]  N. Cheung,et al.  Ifosfamide, carboplatin, and etoposide for neuroblastoma , 2013, Cancer.

[16]  S. Keir,et al.  Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.

[17]  A. Naranjo,et al.  Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Naranjo,et al.  Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group , 2011, Clinical Cancer Research.

[19]  D. Greenblatt,et al.  Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  V. Pistoia,et al.  Cytokines in neuroblastoma: from pathogenesis to treatment. , 2011, Immunotherapy.

[21]  J. Maris,et al.  Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Maris,et al.  Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[24]  B. Brumback,et al.  Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Qin,et al.  Differential impact of high‐dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma , 2010, Cancer.

[26]  S. Grupp,et al.  Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. , 2010, European journal of cancer.

[27]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[28]  S. Parodi,et al.  Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. , 2009, European journal of cancer.

[29]  M. Smyth,et al.  Immunogenic anti-cancer chemotherapy as an emerging concept. , 2008, Current opinion in immunology.

[30]  J. Dufour,et al.  Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. , 2008, Journal of hepatology.

[31]  S. Eksborg,et al.  Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo , 2008, Oncogene.

[32]  S. Keir,et al.  Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program , 2008, Pediatric blood & cancer.

[33]  J. Chewning,et al.  Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands1 , 2007, The Journal of Immunology.

[34]  F. Berthold,et al.  Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial , 2007, Journal of Cancer Research and Clinical Oncology.

[35]  F. Berthold,et al.  Topotecan and Etoposide in the Treatment of Relapsed High-risk Neuroblastoma: Results of a Phase 2 Trial , 2007, Journal of pediatric hematology/oncology.

[36]  Su-Chun Cheng,et al.  Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma , 2006, Pediatric blood & cancer.

[37]  N. Cheung,et al.  Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  A. Vickers,et al.  FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[40]  Boris Freidlin,et al.  Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Mackensen,et al.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[42]  G. Mills,et al.  Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells , 2004, Clinical Cancer Research.

[43]  L. Moretta,et al.  Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[45]  G. Severi,et al.  A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma , 2003, Cancer.

[46]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  A. Nowak,et al.  Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. , 2003, Cancer research.

[48]  Seth M Steinberg,et al.  Early selection in a randomized phase II clinical trial , 2002, Statistics in medicine.

[49]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[50]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[51]  S. Holden,et al.  Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[53]  M. Uttenreuther-Fischer,et al.  Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Månsson,et al.  Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. , 1994, Biochimica et biophysica acta.

[55]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[56]  N. Cheung,et al.  Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. , 1985, Cancer research.

[57]  D. Cheresh,et al.  Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. , 1984, Cancer research.

[58]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[59]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[60]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[61]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[62]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.